Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

BACKGROUND: Identifying the patients who may benefit the most from immune checkpoints inhibitors remains a great challenge for clinicians. Here we investigate on blood serum amyloid A (SAA) as biomarker of response to upfront pembrolizumab in patients with advanced non-small-cell lung cancer (NSCLC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Noia, Vincenzo, D’Argento, Ettore, Pilotto, Sara, Vita, Emanuele, Ferrara, Miriam Grazia, Damiano, Paola, Ribelli, Marta, Cannella, Antonella, Virtuoso, Antonella, Fattorossi, Andrea, Ceresoli, Giovanni Luca, Milella, Michele, Beretta, Giordano Domenico, Tortora, Giampaolo, Bria, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139913/
https://www.ncbi.nlm.nih.gov/pubmed/33231726
http://dx.doi.org/10.1007/s00262-020-02788-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139913/
https://www.ncbi.nlm.nih.gov/pubmed/33231726
http://dx.doi.org/10.1007/s00262-020-02788-1

Ejemplares similares